CJC-1295

Description

What It Is

Ipamorelin + CJC-1295 (no DAC) is a combination of two peptides that work through different pathways to stimulate your body’s natural growth hormone production. Ipamorelin triggers GH release from stored reserves. CJC-1295 promotes both GH production and release. Together, they produce 2-3x more GH than either peptide alone.

This combination is popular because ipamorelin is the “cleanest” GH peptide available. It doesn’t raise cortisol, doesn’t spike prolactin, and doesn’t cause the extreme hunger that other GH peptides like GHRP-6 are known for.

How It Works

• GHRH receptor activation: Binds GHRH receptors on anterior pituitary somatotrophs, triggering GH release (physiologic pulsatility is largely preserved while baseline GH may rise).
• Albumin binding via DAC: The DAC moiety binds circulating albumin, protecting against rapid degradation and prolonging half-life, resulting in multi-day elevations in GH/IGF-1 signals in research models.

Pharmacology: DAC vs No-DAC

• With DAC: Effective half-life typically ~6–8 days in humans, with IGF-1 elevations that can persist for a week or longer and may accumulate with repeat dosing in research settings.
• Without DAC: Short half-life (minutes to a few hours), requiring daily or multiple-daily administration to generate repeated GH pulses.
  Bottom line: DAC favors sustained exposure; no-DAC favors pulsatile, time-limited peaks.

Research Findings (What Studies Show)

Early Phase I/II trials reported sustained, dose-dependent increases in GH and IGF-1 after subcutaneous CJC-1295 (DAC), with short-term tolerability observed in healthy adults. Magnitude and duration vary by dose, schedule, and model design.

Stacking in Research

Frequently co-investigated with ghrelin-receptor agonists (e.g., Ipamorelin, GHRP-2/6) to examine complementary pathways (GHRH + ghrelin). Such combinations can augment GH dynamics but may increase the potential for adverse effects, warranting careful study design and monitoring.

Safety & Considerations

• IGF-1 physiology: Prolonged high IGF-1 is theoretically pro-proliferative; research involving active malignancy is typically excluded.
• Signals & limits: Literature includes serious adverse events in trials (e.g., a cardiac-related death temporally associated with study participation; causality not established). Long-term safety for cosmetic/performance outcomes remains insufficiently characterized.
• General caution: Align protocols with ethical approvals and appropriate oversight.

Specifications

• Form: Lyophilized peptide
• Purity: ≥98% (HPLC)
• Appearance: White/off-white powder
• Storage: Store dry at –20 °C; once reconstituted, refrigerate; minimize freeze–thaw cycles
• Solubility: Bacteriostatic water or suitable research solvent

Chemical Information

• Type: GHRH(1-29) analogue + DAC (albumin-binding modification)
• Sequence (core): GHRH(1-29) analog (e.g., MOD GRF (1-29) backbone) with DAC conjugation
• Molecular Formula / Weight: Varies by exact modification and salt form; use COA values

Legal & Compliance Notice

For laboratory research use only. Not for human consumption, medical, or veterinary use. Not a drug, vitamin, or dietary supplement. Information provided for educational and research purposes.